舒尼替尼
索拉非尼
贝伐单抗
医学
药品
转移
药理学
血管生成
单克隆抗体
靶向治疗
癌症研究
不利影响
机制(生物学)
化疗
癌症
免疫学
内科学
抗体
肝细胞癌
哲学
认识论
作者
Jianfang Shao,Bin Dong,Qinghua Zhang
标识
DOI:10.3760/cma.j.issn.1008-6315.2019.05.022
摘要
Angiogenesis plays an important role in the occurrence, development and metastasis of malignant tumors, and anti-angiogenesis has become an important therapeutic method in molecular targeted therapy of tumors.At present, the commonly used anti-angiogenesis drugs include monoclonal antibodies (bevacizumab), tyrosine kinase inhibitors (sorafenib, sunitinib), and endothelial cell growth inhibitors.The adverse reactions of different kinds of targeted anti-angiogenesis drugs are different.To grasp the mechanism of adverse reactions and the treatment measures of related adverse reactions of these drugs will improve the tolerance of patients receiving this kind of drugs, and at the same time, the prognosis of patients will be further improved.
Key words:
Targeted therapy of tumor; Anti-angiogenie drugs; Adverse reactions
科研通智能强力驱动
Strongly Powered by AbleSci AI